Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
10-01-02-02 Local corticosteroids injections
| Methylprednisolone Acetate with Lidocaine Depo-Medrone® |
|
Formulary
|
Injection |
|
| Triamcinolone Acetonide Adcortyl® |
|
Formulary
|
| Injection 10mg/1mL Intra-articular/intra-dermal injection |
|
|
| Triamcinolone Acetonide Kenalog® |
|
Formulary
|
| Injection 40mg/1mL Intra-articular/intramuscular injection |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG100: Rheumatoid arthritis in adults: management
- NICE NG219: Gout: diagnosis and management
- NICE NG226: Osteoarthritis in over 16s: diagnosis and management
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)